Gerdau S.A. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Gerdau S.A. Common Stock trades at $5.07 (market cap $9.16B), while State Street SPDR S&P Biotech ETF trades at $152.76 (market cap $10.11B). The key difference: Gerdau S.A. Common Stock and State Street SPDR S&P Biotech ETF are close in size by market cap, and Gerdau S.A. Common Stock pays a 3.67% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| GGB | XBI | |
|---|---|---|
Market Cap | $9.16B | $10.11B |
Volume | 16,238,936 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $5.17 | $169.55 |
52-Week Low | $3.15 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $11.10B | — |
Dividend Yield | 3.67% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →